CJC-1295 no DAC and Sermorelin compared: chemistry, targets and regulatory records
CJC-1295 without DAC and sermorelin are both 29-residue amidated analogues of the N-terminal fragment of growth hormone-releasing hormone. They differ at four positions.
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
How do CJC-1295 no DAC and Sermorelin differ on the facts?
| Fact | CJC-1295 no DAC | Sermorelin |
|---|---|---|
| Class | GHRH(1-29) analogue, amidated | GHRH(1-29) fragment, amidated |
| Length | 29 residues | 29 residues |
| Molecular formula | C152H252N44O42 | C149H246N44O42S |
| Average molecular weight | 3367.9 g/mol | 3357.9 g/mol |
| Receptor or pathway background | Growth hormone-releasing hormone receptor | Growth hormone-releasing hormone receptor |
| FDA (Drugs@FDA) | No application listed | 2 applications listed (Discontinued) |
| EMA (centrally authorised) | No centrally authorised medicine listed | No centrally authorised medicine listed |
| MHRA (Products) | No product document found | No product document found |
| WADA 2026 list | Named, S2.2.4 | Named, S2.2.4 |
| Studies in our library | 6 | 5 |
| PubMed records for the search terms | 34 | 365 |
| Registered studies (ClinicalTrials.gov) | 1 | 27 |
Data dates: chemistry checked against PubChem 2026-10-05; regulatory records 2026-10-05; WADA list 2026-10-05; PubMed counts 2026-10-05.
What do the cited papers say differs between CJC-1295 no DAC and Sermorelin?
- The sequences differ at positions 2 (D-Ala for Ala), 8 (Gln for Asn), 15 (Ala for Gly) and 27 (Leu for Met), computed from the catalog sequence of CJC-1295 without DAC and residues 1 to 29 of the sequence in the 1982 isolation paper.[3]
- Clinical papers on CJC-1295 describe the albumin-binding form, not the unconjugated peptide compared here.[2],[1]
- Both are named in the WADA 2026 Prohibited List under S2.2.4.
Nothing on this page ranks one compound above the other or states what either does for a person.
Which studies are cited on this page?
[1] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91:4792-7.
Examined the pulsatile pattern of growth hormone secretion in healthy adults during continuous CJC-1295 exposure (the albumin-binding form).
[2] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805.
Randomised, placebo-controlled trials in healthy adults reporting pharmacokinetics, GH and IGF-I pharmacodynamics and safety of CJC-1295 (the albumin-binding form).
[3] Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218:585-7.
Isolation and amino-acid sequence of a 44-residue growth hormone-releasing peptide from a human pancreatic tumour, with a synthetic replicate.